AbbVie announced final Phase 3 results from the CLL14 trial showing that a fixed-duration venetoclax plus obinutuzumab treatment significantly improves progression-free survival (PFS) in previously untreated chronic lymphocytic leukemia (CLL) patients compared to chlorambucil plus obinutuzumab. The nine-year data revealed a median PFS of 6.4 years versus 3.2 years and a median time to next treatment of 7.6 years, highlighting durable efficacy and safety. This supports venetoclax-based regimens as a first-line treatment offering patients longer treatment-free periods. The trial enrolled 432 patients with coexisting conditions, confirming the combination's benefit in unfit patients.
AbbVie shares have risen over 53% in 2024 driven by strong sales of immunology drugs Skyrizi and Rinvoq, which are offsetting Humira's decline faster than expected. However, the company faces challenges with a negative shareholders’ equity of -$6.6 b...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
Verizon, Chevron, and AbbVie have all raised their dividends in 2026, appealing to retirees and income-focused investors seeking reliable payouts amid market volatility. Verizon offers a high yield of around 6% with strong cash flow and recent growth...
AbbVie received a Complete Response Letter from the FDA regarding its application for TrenibotE, a fast-acting botulinum neurotoxin serotype E for treating moderate to severe glabellar lines. The FDA's concerns were limited to manufacturing process d...
AbbVie presented new clinical data at the European Hematology Association (EHA) 2026 Congress showcasing progress in treatments for various blood cancers, including multiple myeloma, follicular lymphoma, and leukemia. Key highlights include promising...
